The United States Food and Drug Administration (FDA) has issued its 2018-2020 Strategic Priorities. FDA's measure of success is that by December 31, 2020, more than 50 percent of manufacturers of novel technologies for the U.S. market intend to bring their devices to the U.S. first or in parallel with other major markets. FDA seeks to achieve this goal through the systematic application of the following three approaches:
- Employee Engagement, Opportunity, and Success
- Collaborative Communities
In using these approaches FDA will continue to work and build on its 2016-2017 Strategic Priorities, such as establishing the National Evaluation System for health Technology (NEST) and partnering with patients. Along with the release of its 2018-2020 Strategic Priorities, FDA is providing an update on its 2016-2017 Strategic Priorities, for which it has met or exceeded all of its goals. Already, FDA is seeing the impact of its investments in accomplishing these priorities. For example, in calendar year 2017, FDA approved the largest number of medical devices in the history of the program – 95 – continuing an almost annual increase in novel device approvals since 2009.